The aim of this study is to prospectively collect clinical information on patients with extranodal lymphoma, and to explore the best therapeutic strategies in the real-world population.
Age ≥ 18 years (including 18 years old).
Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined.
Patients who have received systematic clinical treatment.
Patients with measurable lesions, at least containing one effective evaluation of efficacy.
Patients who only receive supportive treatment.
Patients who cannot obtain effective evaluation data of efficacy.
Adult patients with histologically confirmed diagnosis of non-Hodgkin lymphoma with extranodal involvement.
Cohort
Prospective
No interventions need to be specified for this study
Other interventionNo interventions need to be specified for this study
Progression Free Survival (PFS)
Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.
Overall Survival (OS)
Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
